OKYO
OKYO Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$1.40
−0.71%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -43.1%
- EBIT
- -28.0%
- EPS
- -99.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +74.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -19.5%
- EBIT
- -18.2%
- Net income
- -90.2%
- EPS
- -100.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026